VVUS News $VVUS
Nasdaq stocks posting largest volume increases
AP - 36 mins ago
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - 36 mins ago
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Rite Aid and Pier 1 are big market movers
AP - 1 hr 15 mins ago
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
Vivus Set to Possibly Pullback After Yesterday's Rally of 12.37%
Comtex SmarTrend(R) - 1 hr 25 mins ago
Vivus (NASDAQ:VVUS) traded in a range yesterday that spanned from a low of $4.21 to a high of $4.82. Yesterday, the shares gained 12.4%, which took the trading range above the 3-day high of $4.07 on volume of 34.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why VIVUS, Inc. Is Today's Best Biotech Stock
Sean Williams, The Motley Fool - Motley Fool - Thu Sep 18, 12:26PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of VIVUS , a biopharmaceutical company...
FDA OKs faster-acting label for ED drug Stendra
By The Associated Press - AP - Thu Sep 18, 11:21AM CDT
Federal regulators have approved a new label for Vivus' impotence drug, stating that it becomes effective in half the time that the previous label had stated.
Hot Stock: Vivus, Shares Gain 10.8% (VVUS)
Comtex SmarTrend(R) - Thu Sep 18, 10:08AM CDT
Vivus (NASDAQ:VVUS) is one of today's best performing low-priced stocks, up 10.8% to $4.30 on 10.1x average daily volume. Vivus has traded 14.0 million shares thus far today, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (10.8% to the Dow's 0.5%) and outperformed the S&P 500 (10.8% to the S&P's 0.4%) during today's trading.
Why VIVUS (VVUS) Stock Is Up Today
at The Street - Thu Sep 18, 9:17AM CDT
Shares of VIVUS (VVUS) were up in morning trading Thursday after the FDA approved the company's erectile dysfunction drug Stendra.
VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity
Marketwire - Thu Sep 18, 5:01AM CDT
VIVUS, Inc. (NASDAQ: VVUS) and Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for STENDRA® (avanafil). STENDRA is now the only FDA-approved erectile dysfunction (ED) medication indicated to be taken as early as approximately 15 minutes before sexual activity.
VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity
PR Newswire - Thu Sep 18, 5:00AM CDT
VIVUS, Inc. (Nasdaq: VVUS) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for STENDRA® (avanafil). STENDRA is now the only FDA-approved erectile dysfunction (ED) medication indicated to be taken as early as approximately 15 minutes before sexual activity.
5 Things Arena Pharmaceuticals, Inc.'s Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Wed Sep 17, 9:51AM CDT
Arena Pharmaceuticals held a press conference in conjunction with its second-quarter earnings to let investors know what's happening with its obesity drug Belviq and the rest of its pipeline. Below, you'll find five quotes from the call that...
Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy
at The Street - Tue Sep 16, 8:48AM CDT
Patients lost 12% of their body weight following 12 weeks of treatment with Arena's Belviq plus phentermine.
2 New Diet Drugs Coming Soon?
George Budwell, The Motley Fool - Motley Fool - Sat Sep 13, 1:05PM CDT
America's love of "supersized" everything has helped fuel an out-of-control obesity problem that is having dire consequences on human health and the economy. For instance, the CDC estimates that the annual medical cost of obesity in the U.S., as of...
Business Highlights
By The Associated Press - AP - Thu Sep 11, 4:57PM CDT
___
FDA panel backs Novo Nordisk injection for obesity
AP - Thu Sep 11, 4:42PM CDT
WASHINGTON (AP) — Federal health experts say a diabetes drug from Novo Nordisk should be approved for a new use in treating obesity.
FDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity Drug
Brian Orelli, The Motley Fool - Motley Fool - Thu Sep 11, 3:46PM CDT
Source: Takeda Pharmaceuticals Patients now have a third drug to treat their obesity. Today, Orexigen and Takeda Pharmaceuticals announced that the Food and Drug Administration approved its obesity drug Contrave . (The FDA made the same...
How Will Orexigen Therapeutics (OREX) Stock Respond to FDA's Contrave Approval?
at The Street - Thu Sep 11, 3:10PM CDT
Shares of Orexigen Therapeutics (OREX) were down in afternoon trading Thursday despite the FDA's approval of the company's diet pill Contrave.
FDA approves weight-loss drug Contrave
By MATTHEW PERRONE - AP - Thu Sep 11, 12:49PM CDT
WASHINGTON (AP) — U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation's 78 million obese adults.
Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised
at The Street - Thu Sep 11, 12:23PM CDT
Orexigen's Contrave must prove it can top the dismal obesity pill launches of its competitors Arena and Vivus.
Nasdaq stocks posting largest volume increases
AP - 36 mins ago
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - 36 mins ago
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Rite Aid and Pier 1 are big market movers
AP - 1 hr 15 mins ago
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
Vivus Set to Possibly Pullback After Yesterday's Rally of 12.37%
Comtex SmarTrend(R) - 1 hr 25 mins ago
Vivus (NASDAQ:VVUS) traded in a range yesterday that spanned from a low of $4.21 to a high of $4.82. Yesterday, the shares gained 12.4%, which took the trading range above the 3-day high of $4.07 on volume of 34.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why VIVUS, Inc. Is Today's Best Biotech Stock
Sean Williams, The Motley Fool - Motley Fool - Thu Sep 18, 12:26PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of VIVUS , a biopharmaceutical company...
FDA OKs faster-acting label for ED drug Stendra
By The Associated Press - AP - Thu Sep 18, 11:21AM CDT
Federal regulators have approved a new label for Vivus' impotence drug, stating that it becomes effective in half the time that the previous label had stated.
Hot Stock: Vivus, Shares Gain 10.8% (VVUS)
Comtex SmarTrend(R) - Thu Sep 18, 10:08AM CDT
Vivus (NASDAQ:VVUS) is one of today's best performing low-priced stocks, up 10.8% to $4.30 on 10.1x average daily volume. Vivus has traded 14.0 million shares thus far today, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (10.8% to the Dow's 0.5%) and outperformed the S&P 500 (10.8% to the S&P's 0.4%) during today's trading.
Why VIVUS (VVUS) Stock Is Up Today
at The Street - Thu Sep 18, 9:17AM CDT
Shares of VIVUS (VVUS) were up in morning trading Thursday after the FDA approved the company's erectile dysfunction drug Stendra.
VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity
Marketwire - Thu Sep 18, 5:01AM CDT
VIVUS, Inc. (NASDAQ: VVUS) and Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for STENDRA® (avanafil). STENDRA is now the only FDA-approved erectile dysfunction (ED) medication indicated to be taken as early as approximately 15 minutes before sexual activity.
VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity
PR Newswire - Thu Sep 18, 5:00AM CDT
VIVUS, Inc. (Nasdaq: VVUS) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for STENDRA® (avanafil). STENDRA is now the only FDA-approved erectile dysfunction (ED) medication indicated to be taken as early as approximately 15 minutes before sexual activity.
5 Things Arena Pharmaceuticals, Inc.'s Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Wed Sep 17, 9:51AM CDT
Arena Pharmaceuticals held a press conference in conjunction with its second-quarter earnings to let investors know what's happening with its obesity drug Belviq and the rest of its pipeline. Below, you'll find five quotes from the call that...
Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy
at The Street - Tue Sep 16, 8:48AM CDT
Patients lost 12% of their body weight following 12 weeks of treatment with Arena's Belviq plus phentermine.
2 New Diet Drugs Coming Soon?
George Budwell, The Motley Fool - Motley Fool - Sat Sep 13, 1:05PM CDT
America's love of "supersized" everything has helped fuel an out-of-control obesity problem that is having dire consequences on human health and the economy. For instance, the CDC estimates that the annual medical cost of obesity in the U.S., as of...
Business Highlights
By The Associated Press - AP - Thu Sep 11, 4:57PM CDT
___
FDA panel backs Novo Nordisk injection for obesity
AP - Thu Sep 11, 4:42PM CDT
WASHINGTON (AP) — Federal health experts say a diabetes drug from Novo Nordisk should be approved for a new use in treating obesity.
FDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity Drug
Brian Orelli, The Motley Fool - Motley Fool - Thu Sep 11, 3:46PM CDT
Source: Takeda Pharmaceuticals Patients now have a third drug to treat their obesity. Today, Orexigen and Takeda Pharmaceuticals announced that the Food and Drug Administration approved its obesity drug Contrave . (The FDA made the same...
How Will Orexigen Therapeutics (OREX) Stock Respond to FDA's Contrave Approval?
at The Street - Thu Sep 11, 3:10PM CDT
Shares of Orexigen Therapeutics (OREX) were down in afternoon trading Thursday despite the FDA's approval of the company's diet pill Contrave.
FDA approves weight-loss drug Contrave
By MATTHEW PERRONE - AP - Thu Sep 11, 12:49PM CDT
WASHINGTON (AP) — U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation's 78 million obese adults.
Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised
at The Street - Thu Sep 11, 12:23PM CDT
Orexigen's Contrave must prove it can top the dismal obesity pill launches of its competitors Arena and Vivus.
